Mayo Clinic and Lifepoint Health are suing Bristol Myers Squibb and its subsidiary, Celgene, alleging the companies inflated the price of the cancer drug Revlimid by paying other drugmakers to keep their generic versions off the market, theSan Francisco Business Times reported Oct. 16.
Read the full post on Becker's Hospital Review - Healthcare News
